中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 10
Oct.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(10): 1988-1993

Advances in the basic research on traditional Chinese medicine for prevention and treatment of hepatic fibrosis based on omics technology

DOI: 10.12449/JCH251005
  • 1.

    Frontiers Medical Center，Tianfu Jincheng Laboratory，Chengdu 610212，China

  • 2.

    School of Life Sciences Beijing University of Chinese Medicine Beijing 100029，China

  • 3.

    School of Traditional Chinese Medicine，Beijing University of Chinese Medicine，Beijing 100029，China

  • 4.

    Institute of Integrated Chinese and Western Medicine，Fujian University of Traditional Chinese Medicine，Fuzhou 350122，China

  • 5.

    Second Department of Integrated Traditional Chinese and Western Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

National Key R&D Program Research on Modernization of Traditional Chinese Medicine (2022YFC3502100)

More Information
  • Corresponding author: LI Xiaojiaoyang， xiaojiaoyang.li@bucm.edu.cn （ORCID： 0000-0003-0291-5856）
  • Received Date: 2025-06-27
  • Accepted Date: 2025-08-02
  • Published Date: 2025-10-25
    Abstract
  • Hepatic fibrosis is the common key pathological link of various chronic liver diseases and can progress to malignant diseases such as liver cirrhosis and hepatocellular carcinoma； however， there is still a lack of effective targeted therapeutic drugs at present. Traditional Chinese medicine （TCM） has a marked clinical effect in the prevention and treatment of hepatic fibrosis， yet its precise clinical application and global promotion are greatly limited by the complex components of compound prescriptions and unclear mechanism of action. In recent years， multimodal high-throughput omics technology has achieved rapid development， providing strong technical support for elaborating on the scientific connotation of TCM in the treatment of complex diseases due to its advantages of systematic profiling， big-data analytics， and precise target prediction. In particular， integrated transcriptomic， proteomic， and metabolomic strategies comprehensively elucidate key signaling networks， cellular phenotypic transitions， and extracellular matrix metabolic homeostasis modulated by TCM compounds and monomers and assist in the screening and assessment of effective component groups and novel biomarkers. This article systematically reviews the advances in basic research on TCM prevention and treatment of hepatic fibrosis based on multi-omics technologies in the past five years， summarizes the “drug-target-pathway-phenotype” regulatory network， and elaborates on the core mechanisms of TCM in regulating hepatic stellate cell activation and reversing hepatic fibrosis. Future studies should further delve into the interdisciplinary integration and dynamic analytical methodologies of multi-omics technologies， precisely identify the core regulatory target networks modulated by TCM， and systematically unravel the scientific connotation of compatibility rule in compound prescriptions， in order to provide a theoretical basis for developing efficient targeted drugs for hepatic fibrosis and individualized diagnosis and treatment strategies.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    GUO C, LAI LY, MA BY, et al. Notoginsenoside R1 targets PPAR-γ to inhibit hepatic stellate cell activation and ameliorates liver fibrosis[J]. Exp Cell Res, 2024, 437( 1): 113992. DOI: 10.1016/j.yexcr.2024.113992.
    [2]
    BAI YM, LIANG S, ZHOU YH, et al. Transcriptomic analysis reveals pharmacological mechanisms mediating efficacy of Yangyinghuoxue Decoction in CCl4-induced hepatic fibrosis in rats[J]. Front Pharmacol, 2024, 15: 1364023. DOI: 10.3389/fphar.2024.1364023.
    [3]
    ZHANG JJ, ZHANG JX, FENG QY, et al. Eriocitrin ameliorates hepatic fibrosis and inflammation: The involvement of PPARα-mediated NLRP1/NLRC4 inflammasome signaling cascades[J]. J Ethnopharmacol, 2025, 338( Pt 3): 119119. DOI: 10.1016/j.jep.2024.119119.
    [4]
    YANG Y, SUN MY, LI WD, et al. Rebalancing TGF-β/Smad7 signaling via Compound Kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis[J]. Clin Transl Med, 2021, 11( 7): e410. DOI: 10.1002/ctm2.410.
    [5]
    ZHOU QM, ZHANG X, CHEN S, et al. Shugan Jianpi Formula attenuate liver fibrosis via regulation of miR-193a-3p/TGF-β2 in hepatic stellate cells: An in vivo and in vitro study[J]. J Ethnopharmacol, 2025, 340: 119120. DOI: 10.1016/j.jep.2024.119120.
    [6]
    CHEN XF, WANG YM, JI SX, et al. Hepatoprotective efficacy and interventional mechanism of Qijia Rougan decoction in liver fibrosis[J]. Front Pharmacol, 2022, 13: 911250. DOI: 10.3389/fphar.2022.911250.
    [7]
    XIONG Y, HU JY, XUAN C, et al. Transcriptome analysis reveals the molecular mechanism of Yiqi Rougan decoction in reducing CCl4-induced liver fibrosis in rats[J]. Chin Med, 2021, 16( 1): 142. DOI: 10.1186/s13020-021-00552-w.
    [8]
    WANG T, ZHU JH, GAO LH, et al. Identification of circular RNA biomarkers for Pien Tze Huang treatment of CCl4-induced liver fibrosis using RNA-sequencing[J]. Mol Med Rep, 2022, 26( 4): 309. DOI: 10.3892/mmr.2022.12825.
    [9]
    DENG J, LONG J, YANG Y, et al. Gentiana decoction inhibits liver fibrosis and the activation of hepatic stellate cells via upregulating the expression of Parkin[J]. Fitoterapia, 2024, 178: 106170. DOI: 10.1016/j.fitote.2024.106170.
    [10]
    MA Z, XUE XY, BAI JZ, et al. Si-Wu-Tang ameliorates bile duct ligation-induced liver fibrosis via modulating immune environment[J]. Biomed Pharmacother, 2022, 155: 113834. DOI: 10.1016/j.biopha.2022.113834.
    [11]
    LAN T, CHEN B, HU XZ, et al. Tianhuang formula ameliorates liver fibrosis by inhibiting CCL2-CCR2 axis and MAPK/NF-κB signaling pathway[J]. J Ethnopharmacol, 2024, 321: 117516. DOI: 10.1016/j.jep.2023.117516.
    [12]
    MENG Q, ZHU HW, LI YY, et al. Quantitative proteomics reveals the protective effects of Yinchenzhufu decoction against cholestatic liver fibrosis in mice by inhibiting the PDGFRβ/PI3K/AKT pathway[J]. Front Pharmacol, 2024, 15: 1341020. DOI: 10.3389/fphar.2024.1341020.
    [13]
    GONG PY, YIN KH, LUO XM, et al. Tandem mass tag-based proteomics analysis reveals the multitarget mechanisms of Phyllanthus emblica against liver fibrosis[J]. Front Pharmacol, 2022, 13: 989995. DOI: 10.3389/fphar.2022.989995.
    [14]
    CHEN XF, SUN X, JI SX, et al. TMT-based proteomics analysis identifies the interventional mechanisms of Qijia Rougan decoction in improving hepatic fibrosis[J]. J Ethnopharmacol, 2024, 319( Pt 3): 117334. DOI: 10.1016/j.jep.2023.117334.
    [15]
    ZHANG JB, JIN HL, FENG XY, et al. The combination of Lonicerae Japonicae Flos and Forsythiae Fructus herb-pair alleviated inflammation in liver fibrosis[J]. Front Pharmacol, 2022, 13: 984611. DOI: 10.3389/fphar.2022.984611.
    [16]
    ZHANG YM, ZHAO M, LIU YY, et al. Investigation of the therapeutic effect of Yinchen Wuling Powder on CCl4-induced hepatic fibrosis in rats by 1H NMR and MS-based metabolomics analysis[J]. J Pharm Biomed Anal, 2021, 200: 114073. DOI: 10.1016/j.jpba.2021.114073.
    [17]
    WANG C, MA C, FU K, et al. Hepatoprotective effect of phillygenin on carbon tetrachloride-induced liver fibrosis and its effects on short chain fatty acid and bile acid metabolism[J]. J Ethnopharmacol, 2022, 296: 115478. DOI: 10.1016/j.jep.2022.115478.
    [18]
    YANG YX, CHEN YC, FENG DG, et al. Ficus hirta Vahl. ameliorates liver fibrosis by triggering hepatic stellate cell ferroptosis through GSH/GPX4 pathway[J]. J Ethnopharmacol, 2024, 334: 118557. DOI: 10.1016/j.jep.2024.118557.
    [19]
    HAO M, CHEN ZY, WANG PP, et al. Bioactive fraction of processed Curcumae Rhizoma-Sparganii Rhizoma anti-liver fibrosis by regulate taurine metabolism through PI3K/AKT pathway[J]. J Ethnopharmacol, 2025, 351: 120090. DOI: 10.1016/j.jep.2025.120090.
    [20]
    CHEN Y, LIAO W, ZHU ZP, et al. Essential oil from the raw and vinegar-processed Rhizoma Curcumae ameliorate CCl4-induced liver fibrosis: Integrating network pharmacology and molecular mechanism evaluation[J]. Food Funct, 2021, 12( 9): 4199- 4220. DOI: 10.1039/d0fo03052j.
    [21]
    ZHOU Y, WU R, CAI FF, et al. Xiaoyaosan decoction alleviated rat liver fibrosis via the TGFβ/Smad and Akt/FoxO3 signaling pathways based on network pharmacology analysis[J]. J Ethnopharmacol, 2021, 264: 113021. DOI: 10.1016/j.jep.2020.113021.
    [22]
    YAN D, ZHANG XL, MA CM, et al. Mechanism study of Xiaoyao San against nonalcoholic steatohepatitis-related liver fibrosis based on a combined strategy of transcriptome analysis and network pharmacology[J]. Pharmaceuticals(Basel), 2024, 17( 9): 1128. DOI: 10.3390/ph17091128.
    [23]
    HONG B, WANG YP, HOU YJ, et al. Study on the mechanism of anti-hepatic fibrosis of Glycyrrhiza Uralensis-Salvia miltiorrhiza prescription based on serum and urine metabolomics and network pharmacology[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2022, 1209: 123416. DOI: 10.1016/j.jchromb.2022.123416.
    [24]
    LI Y, LI MX, MAO J, et al. The processing mechanism of vinegar-processed Curcumae Rhizome enhances anti hepatic fibrotic effects through regulation of PI3K/Akt/mTOR signaling pathway[J]. Phytomedicine, 2024, 135: 156098. DOI: 10.1016/j.phymed.2024.156098.
    [25]
    CAO KF, JIANG H, ZHANG LL, et al. Effective components and molecular mechanism of Biejiaruangan capsule against liver fibrosis: High-resolution mass spectrometry, network pharmacological analysis and experimental verification[J]. Comb Chem High Throughput Screen, 2024. DOI: 10.2174/0113862073338867240930031800.[ Epub ahead of print]
    [26]
    CHEN ST, ZHU YP, WANG JX, et al. Biejia Ruangan tablet alleviated liver fibrosis in murine models by hindering the crosstalk between hepatic stellate cells and M2-like macrophages through PDGF-AA/PI3K/AKT pathway[J]. J Ethnopharmacol, 2025, 350: 120029. DOI: 10.1016/j.jep.2025.120029.
    [27]
    WU JZ, GONG LP, LI YF, et al. Tao-Hong-Si-Wu-Tang improves thioacetamide-induced liver fibrosis by reversing ACSL4-mediated lipid accumulation and promoting mitophagy[J]. J Ethnopharmacol, 2024, 333: 118456. DOI: 10.1016/j.jep.2024.118456.
    [28]
    ZHU JH, ZHANG D, WANG T, et al. Target identification of hepatic fibrosis using Pien Tze Huang based on mRNA and lncRNA[J]. Sci Rep, 2021, 11( 1): 16980. DOI: 10.1038/s41598-021-96459-5.
    [29]
    LIU ZY, XIANG HY, XIANG DJ, et al. Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence[J]. Chin Med, 2022, 17( 1): 23. DOI: 10.1186/s13020-022-00579-7.
    [30]
    YANG YH, LIU Y, CHENG YJ, et al. Multi-omics and experimental analysis unveil the key components in Scutellaria baicalensis Georgi to alleviate hepatic fibrosis via regulating cPLA2-mediated arachidonic acid metabolism[J]. J Transl Med, 2024, 22( 1): 1138. DOI: 10.1186/s12967-024-05955-5.
    [31]
    GAO Y, WU H, LUO YQ, et al. Mechanisms of dihydromyricetin for improving hepatic fibrosis through the integration of metabolomics and gut microbiota[J]. Am J Chin Med, 2025, 53( 3): 889- 908. DOI: 10.1142/S0192415X25500338.
    [32]
    ZHANG YM, ZHAO M, JIANG X, et al. Comprehensive analysis of fecal microbiome and metabolomics in hepatic fibrosis rats reveal hepatoprotective effects of Yinchen Wuling Powder from the host-microbial metabolic axis[J]. Front Pharmacol, 2021, 12: 713197. DOI: 10.3389/fphar.2021.713197.
    [33]
    LI X, XU XY, TAO SA, et al. Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl4-induced hepatic fibrosis[J]. Front Pharmacol, 2024, 15: 1347120. DOI: 10.3389/fphar.2024.1347120.
    [34]
    CUI XY, ZHANG RH, LI YF, et al. Bie Jia Jian pill ameliorates BDL-induced cholestatic hepatic fibrosis in rats by regulating intestinal microbial composition and TMAO-mediated PI3K/AKT signaling pathway[J]. J Ethnopharmacol, 2025, 337( Pt 2): 118910. DOI: 10.1016/j.jep.2024.118910.
    [35]
    ZHAO YH, ZHAO M, ZHANG YM, et al. Bile acids metabolism involved in the beneficial effects of Danggui Shaoyao San via gut microbiota in the treatment of CCl4 induced hepatic fibrosis[J]. J Ethnopharmacol, 2024, 319( Pt 3): 117383. DOI: 10.1016/j.jep.2023.117383.
    [36]
    YANG SY, CHENG YJ, WANG XL, et al. Chinese herbal decoction, Yi-Qi-Jian-Pi formula exerts anti-hepatic fibrosis effects in mouse models of CCl4-induced liver fibrosis[J]. Heliyon, 2024, 10( 5): e26129. DOI: 10.1016/j.heliyon.2024.e26129.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (73) PDF downloads(22) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return